Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH CirrhosisGlobeNewsWire • 10/21/24
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024GlobeNewsWire • 10/18/24
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor ConferenceGlobeNewsWire • 10/02/24
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals StockThe Motley Fool • 08/14/24
While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH MarketSeeking Alpha • 08/08/24
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/07/24
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024GlobeNewsWire • 07/24/24
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.The Motley Fool • 06/16/24
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressGlobeNewsWire • 06/06/24
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASHInvestors Business Daily • 06/05/24
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/07/24